Gathering the record
Relay is organizing the evidence and source boundaries.
Experimental D-retro-inverso senolytic peptide
FOXO4-DRI is an experimental peptide designed to disrupt an interaction between FOXO4 and p53 in selected senescent-cell models. Cell, tissue, and mouse studies support a plausible senolytic mechanism, but no human administration study has established safety, anti-aging effects, or clinical benefit. One pulmonary-hypertension study also shows why senescent-cell clearance cannot be assumed to help every tissue.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
FOXO4-DRI is an experimental peptide designed to disrupt an interaction between two cell-stress proteins, FOXO4 and p53, in selected senescent cells. Senescent cells have stopped dividing but remain biologically active.
Researchers ask whether selectively removing harmful senescent cells can improve age- or disease-related tissue function. The same cells may also support repair or tumor suppression, so selectivity is a central safety question.
Cell, human-tissue, and mouse studies support a plausible cell-clearing mechanism and report signals in aging, fibrosis, fertility, cartilage, or vascular models. Another pulmonary-hypertension study found worse vascular measures after senescent-cell clearance in selected models. No human administration study was identified.
Human exposure, selectivity, efficacy, pharmacokinetics, immune effects, cancer implications, tissue-repair consequences, and long-term safety remain unknown. Preclinical benefits and harms show why universal anti-aging claims are not justified.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Foundational research investigated FOXO4-DRI in senescence-enriched human fibroblasts outside the body and in progeroid or naturally aged mouse models.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Mechanistic, cell, tissue, and animal studies exist, but no administered human study was identified.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The mechanism is plausible in selected systems while effectiveness and direction can vary by tissue and model.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: No verified study administered FOXO4-DRI to human participants. Cell selectivity and mouse tissue signals cannot establish human anti-aging benefit or resolve repair, vascular, immune, and tumor-suppression risks. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
No administered human study was identified. The closest human-derived evidence is laboratory or ex-vivo work in human fibroblasts, chondrocytes, endothelial cells, and keloid tissue.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether systemic senescent-cell targeting can be selective and safe in people without disrupting protective senescence, tissue repair, tumor suppression, or vulnerable vascular-cell populations.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
It is a research peptide, not a receptor agonist. The design combines a FOXO4-derived sequence with a cell-penetrating segment and reverses peptide direction and chirality to improve stability in experimental systems.
The closest human-derived evidence comes from cells and tissue studied outside the body, including fibroblasts, chondrocytes, and keloid organ cultures.
Published findings describe specific laboratory systems and animal models. They do not establish a whole-body anti-aging treatment in people.
In rodent pulmonary-hypertension models, senescent-cell elimination was associated with pulmonary endothelial-cell loss and worse hemodynamic and remodeling measures.
Each research direction used a different experimental system. None demonstrates a broadly transferable clinical effect.
Animal injection protocols and laboratory concentrations describe experiments; they are not consumer instructions.
Published work describes a protein-interaction mechanism that depends on cellular state, p53 signaling, phosphorylation, uptake, and model-specific biology.
Mechanisms
FOXO4-DRI is a cell-penetrating D-retro-inverso peptide derived from a FOXO4 interaction region. Foundational experiments reported competition with FOXO4 for p53 binding, nuclear redistribution of active p53, and preferential apoptosis in selected senescent fibroblast models, followed by improvements in several mouse tissue-homeostasis measures. Later NMR and biochemical work characterized binding to the intrinsically disordered p53 transactivation domain and the effect of p53 phosphorylation. Additional studies examined expanded human chondrocytes, keloid tissue, pulmonary fibrosis, vascular aging, and aged-mouse spermatogenesis. The evidence remains model dependent, and rodent pulmonary-hypertension work found that senescent-cell clearance, including FOXO4-DRI exposure, could worsen pulmonary vascular outcomes.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Senescent endothelial-cell experiments plus naturally aged and induced-aging mouse models
Endothelial cells and mice
FOXO4-DRI altered FOXO4-p53 signaling, promoted apoptosis in senescent endothelial-cell models, and improved selected vascular-aging measures in mice.
Study administration: FOXO4-DRI injection or control in preclinical protocols
Limitations: The work remains preclinical and does not resolve the contrasting pulmonary-vascular findings or establish cardiovascular safety in humans.
NMR structural modeling, molecular dynamics, and biochemical binding assays
Purified FOXO4 and p53 domains
The study characterized FOXO4-DRI binding to the disordered p53 transactivation domain and showed that p53 phosphorylation can increase binding affinity.
Study administration: FOXO4-DRI, FOXO4 domains, and phosphorylated or unmodified p53 domains
Limitations: Structural and binding data clarify a proposed mechanism but cannot establish cellular selectivity, whole-body safety, or therapeutic benefit.
Single-cell analysis, senescent-fibroblast experiments, and ex-vivo human keloid organ cultures
Human keloid tissue and fibroblasts studied outside the body
FOXO4-DRI promoted apoptosis in senescence-enriched keloid fibroblast models and altered p53 localization in cultured human tissue.
Study administration: FOXO4-DRI under laboratory conditions
Limitations: Ex-vivo tissue and cell findings do not establish keloid prevention, recurrence reduction, wound-healing safety, or clinical treatment benefit.
Senescent Leydig-cell experiments and naturally aged male-mouse study
Laboratory cells and aged male mice
The study reported reduced senescence-associated signaling in Leydig-cell models and improved sperm-quality and spermatogenesis measures in aged mice.
Study administration: FOXO4-DRI or control under preclinical protocols
Limitations: Mouse reproductive-aging findings do not establish fertility, testosterone, or reproductive outcomes in men.
Activated-fibroblast experiments and bleomycin-induced pulmonary fibrosis in mice
Laboratory fibroblasts and mice
FOXO4-DRI reduced selected extracellular-matrix measures in fibroblasts and was associated with less fibrosis and collagen deposition in the mouse model.
Study administration: FOXO4-DRI under laboratory and mouse treatment protocols
Limitations: Bleomycin-induced fibrosis is an experimental model. The findings do not establish safety or benefit in people with pulmonary fibrosis.
Senescent-cell clearance using genetic and pharmacologic approaches across multiple rodent pulmonary-hypertension models
Mice and rats with experimental pulmonary vascular disease
In selected models, senescent-cell elimination, including FOXO4-DRI exposure, was associated with endothelial-cell loss and worse pulmonary-hypertension measures.
Study administration: FOXO4-DRI, ABT263, genetic senescent-cell clearance, or controls
Limitations: The study does not determine human risk or isolate every FOXO4-DRI-specific effect, but it demonstrates that removing senescent cells can be harmful in some disease contexts.
In-vitro comparison of minimally and extensively expanded human chondrocytes
Chondrocytes isolated from healthy human donors
FOXO4-DRI removed a larger fraction of extensively expanded, senescence-enriched chondrocytes than minimally expanded controls and altered subsequent cartilage-related laboratory measures.
Study administration: FOXO4-DRI treatment during in-vitro cell expansion
Limitations: These cells were treated outside the body. The study does not establish joint, cartilage, osteoarthritis, or implantation outcomes in patients.
Mechanistic experiments in senescent human fibroblasts followed by treatment in progeroid and naturally aged mouse models
Laboratory cell models and mice
FOXO4-DRI competed with FOXO4 for p53 binding, preferentially reduced viability in selected senescent fibroblast models, and improved several tissue-homeostasis measures in mouse aging models.
Study administration: FOXO4-DRI or control under laboratory and animal research protocols
Limitations: This foundational work combined cell and mouse models. It did not test safety, pharmacokinetics, longevity, or clinical outcomes in humans, and selectivity may vary across senescent-cell types.
Safety snapshot
Selected cell and mouse studies support a senolytic mechanism, but no administered human outcome study has established safety or effectiveness.
No direct evidenceHuman-derived cells are not human clinical exposure. They cannot establish pharmacokinetics, immune effects, organ toxicity, cancer risk, or clinical benefit.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNot FDA approved; no registered human interventional FOXO4-DRI study was identified at the evidence cutoff Whether systemic senescent-cell targeting can be selective and safe in people without disrupting protective senescence, tissue repair, tumor suppression, or vulnerable vascular-cell populations.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-30
2026-01-15 · PMID 41625068 · DOI 10.3389/fbioe.2025.1729166
2025-06-18 · DOI 10.1038/s41467-025-60844-9
2025-02-24 · PMID 39994346 · DOI 10.1038/s42003-025-07738-0
2024-10-01 · PMID 39025385 · DOI 10.1016/j.exger.2024.112522
2023-10-01 · PMID 37074394 · DOI 10.1007/s00210-023-02452-2
2023-02-21 · PMID 36515093 · DOI 10.1161/CIRCULATIONAHA.122.058794
2021-04-29 · PMID 33996787 · DOI 10.3389/fbioe.2021.677576
2017-03-23 · PMID 28340339 · DOI 10.1016/j.cell.2017.02.031